Skip to main content
SpringerLink
Log in

Antibacterial Agents

  • Chapter
  • First Online:
Infections in Hematology

Abstract

Traditionally, antipseudomonal penicillins combined with an aminoglycoside have been the standard choice for the initial therapy of fever and neutropenia. These regimens were covering primarily Enterobacteriaceae, Pseudomonas aeruginosa, and streptococci. The activity of the former antipseudomonal penicillins (such as carbenicillin, cefsulodin, azlocillin, and ticarcillin) against many Gram-negative rods was, however, rather limited, and the addition of an aminoglycoside was needed to compensate for this limited activity. In the 1980s, ceftazidime was one of the first drugs studied as monotherapy in febrile neutropenia. It was more active in vitro against P. aeruginosa than most of the penicillins and highly active against Escherichia coli and Klebsiella species.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ackerman BH, Patton ML, Guilday RE, et al. Trimethoprim-induced hyperkalemia in burn patients treated with intravenous or oral trimethoprim sulfamethoxazole for methicillin-resistant Staphylococcus aureus and other infections: nature or nurture? J Burn Care Res. 2013;34:127–32.

    PubMed  Google Scholar 

  2. Appelbaum PC, Hunter PA. The fluoroquinolone antibacterials: past, present and future perspectives. Int J Antimicrob Agents. 2000;16:5–15.

    CAS  PubMed  Google Scholar 

  3. Ariano RE, Nyhlén A, Donnelly JP, et al. Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia. Ann Pharmacother. 2005;39:32–8.

    CAS  PubMed  Google Scholar 

  4. Averbuch D, Orasch C, Cordonnier C, et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica. 2013;98:1826–35.

    PubMed Central  PubMed  Google Scholar 

  5. Baglie S, Rosalen PL, Franco LM, et al. Comparative bioavailability of 875 mg amoxicillin tablets in healthy human volunteers. Int J Clin Pharmacol Ther. 2005;43:350–4.

    CAS  PubMed  Google Scholar 

  6. Berry V, Thorburn CE, Knott SJ, et al. Bacteriological efficacies of three macrolides compared with those of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae. Antimicrob Agents Chemother. 1998;42:3193–9.

    CAS  PubMed Central  PubMed  Google Scholar 

  7. Berthoin K, Le Duff CS, Marchand-Brynaert J, et al. Stability of meropenem and doripenem solutions for administration by continuous infusion. J Antimicrob Chemother. 2010;65:1073–5.

    CAS  PubMed  Google Scholar 

  8. Blaser J, König C. Once-daily dosing of aminoglycosides. Eur J Clin Microbiol Infect Dis. 1995;14:1029–38.

    CAS  PubMed  Google Scholar 

  9. Bhavnani SM, Hammel JP, Cirincione BB, Wikler MA, Ambrose PG. Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem. Antimicrob Agents Chemother. 2005;49(9):3944–7.

    CAS  PubMed Central  PubMed  Google Scholar 

  10. Boak LM, Rayner CR, Grayson ML, et al. Clinical population pharmacokinetics and toxicodynamics of linezolid. Antimicrob Agents Chemother. 2014;58:2334–43.

    PubMed Central  PubMed  Google Scholar 

  11. Bookstaver PB, Johnson JW, McCoy TP, et al. Modification of diet in renal disease and modified Cockcroft-Gault formulas in predicting aminoglycoside elimination. Ann Pharmacother. 2008;42:1758–65.

    CAS  PubMed  Google Scholar 

  12. Bow EJ. Point: fluoroquinolone-based antibacterial chemoprophylaxis in neutropenic cancer patients works for defined outcomes in defined populations, but must be used wisely. J Natl Compr Canc Netw. 2004;2(5):433–44.

    CAS  PubMed  Google Scholar 

  13. Boyer A, Gruson D, Bouchet S, et al. Aminoglycosides in septic shock: an overview, with specific consideration given to their nephrotoxic risk. Drug Saf. 2013;36:217–30.

    CAS  PubMed  Google Scholar 

  14. Bubalo JS, Munar MY, Cherala G, et al. Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever. Antimicrob Agents Chemother. 2009;53:428–34.

    CAS  PubMed Central  PubMed  Google Scholar 

  15. Bucaneve G, Miccozzi A, for the GIMEMA Infection Program. Prospective, randomised, multicentre controlled trial on empiric antibiotic therapy in febrile neutropenic cancer patients: piperacillin and tazobactam plus tigecycline versus piperacillin or tazobactam monotherapy. 51st ICAAC, Am Soc Microbiol. 2011, Abstract L1-1503a.

    Google Scholar 

  16. Burgess DS, Summers KK, Hardin TC. Pharmacokinetics and pharmacodynamics of aztreonam administered by continuous intravenous infusion. Clin Ther. 1999;21:1882–9.

    CAS  PubMed  Google Scholar 

  17. Cafiso V, Bertuccio T, Spina D, et al. Modulating activity of vancomycin and daptomycin on the expression of autolysis cell-wall turnover and membrane charge genes in hVISA and VISA strains. PLoS One. 2012;7:e29573.

    CAS  PubMed Central  PubMed  Google Scholar 

  18. Casapao AM, Davis SL, Barr VO, et al. A large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy. Antimicrob Agents Chemother. 2014;58:2541–6.

    PubMed Central  PubMed  Google Scholar 

  19. Casapao AM, Kullar R, Davis SL, et al. Multicenter study of high-dose daptomycin for treatment of enterococcal infections. Antimicrob Agents Chemother. 2013;57:4190–6.

    CAS  PubMed Central  PubMed  Google Scholar 

  20. Catchpole C, Andrews JM, Woodcock J, et al. The comparative pharmacokinetics and tissue penetration of single-dose ciprofloxacin 400 mg i.v. and 750 mg po. J Antimicrob Chemother. 1994;33:103–10.

    CAS  PubMed  Google Scholar 

  21. Chemaly RF, Hanmod SS, Jiang Y, et al. Tigecycline use in cancer patients with serious infections: a report on 110 cases from a single institution. Med (Baltimore). 2009;88:211–20.

    Google Scholar 

  22. Chytra I, Stepan M, Benes J, et al. Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial. Crit Care. 2012;16:R113.

    PubMed Central  PubMed  Google Scholar 

  23. Cometta A, Calandra T, Gaya H, et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother. 1996;40:1108–15.

    CAS  PubMed Central  PubMed  Google Scholar 

  24. Crandon JL, Nicolau DP. Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging gram-negative organisms, including metallo-β-lactamase producers. Antimicrob Agents Chemother. 2013;57:3299–306.

    CAS  PubMed Central  PubMed  Google Scholar 

  25. Daikos GL, Markogiannakis A. Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems? Clin Microbiol Infect. 2011;17:1135–41.

    CAS  PubMed  Google Scholar 

  26. Dalfino L, Puntillo F, Mosca A, et al. High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. Clin Infect Dis. 2012;54:1720–6.

    CAS  PubMed Central  PubMed  Google Scholar 

  27. Dandekar PK, Maglio D, Sutherland CA, et al. Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion. Pharmacotherapy. 2003;23:988–91.

    CAS  PubMed  Google Scholar 

  28. de Aguiar CR, Mourão CI, Rocha MF, et al. Antifolates inhibit Cryptococcus biofilms and enhance susceptibility of planktonic cells to amphotericin B. Eur J Clin Microbiol Infect Dis. 2013;32:557–64.

    Google Scholar 

  29. de Pauw BE, Deresinski SC, Feld R, et al. Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. A multicenter randomized trial. The Intercontinental Antimicrobial Study Group. Ann Intern Med. 1994;120:834–44.

    PubMed  Google Scholar 

  30. del Favero A, Menichetti F, Martino P, et al. A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia. Clin Infect Dis. 2001;33:1295–301.

    PubMed  Google Scholar 

  31. Docobo-Pérez F, López-Cerero L, López-Rojas R, et al. Inoculum effect on the efficacies of amoxicillin-clavulanate, piperacillin-tazobactam, and imipenem against extended-spectrum β-lactamase (ESBL)-producing and non-ESBL-producing Escherichia coli in an experimental murine sepsis model. Antimicrob Agents Chemother. 2013;57:2109–13.

    PubMed Central  PubMed  Google Scholar 

  32. Dryden MS. Linezolid pharmacokinetics and pharmacodynamics in clinical treatment. J Antimicrob Chemother. 2011;66 Suppl 4:7–15.

    Google Scholar 

  33. Durakovic N, Radojcic V, Boban A, et al. Efficacy and safety of colistin in the treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in patients with hematologic malignancy: a matched pair analysis. Intern Med. 2011;50:1009–13.

    CAS  PubMed  Google Scholar 

  34. Egerer G, Goldschmidt H, Salwender H, et al. Efficacy of continuous infusion of ceftazidime for patients with neutropenic fever after high-dose chemotherapy and peripheral blood stem cell transplantation. Int J Antimicrob Agents. 2000;15:119–23.

    CAS  PubMed  Google Scholar 

  35. EUCAST Antimicrobial wild type distributions of microorganisms. 2014. http://mic.eucast.org/Eucast2/. Accessed 1 Feb 2014.

  36. Fainstein V, Bodey GP, Elting L, et al. A randomized study of ceftazidime compared to ceftazidime and tobramycin for the treatment of infections in cancer patients. J Antimicrob Chemother. 1983;12(Suppl A):101–10.

    PubMed  Google Scholar 

  37. Falagas ME, Rafailidis PI, Ioannidou E, et al. Colistin therapy for microbiologically documented multidrug-resistant gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents. 2010;35:194–9.

    CAS  PubMed  Google Scholar 

  38. Feig PU, Mitchell PP, Abrutyn E, et al. Aminoglycoside nephrotoxicity: a double blind prospective randomized study of gentamicin and tobramycin. J Antimicrob Chemother. 1982;10:217–26.

    CAS  PubMed  Google Scholar 

  39. Feld R, dePauw B, Berman S, et al. Meropenem versus ceftazidime in the treatment of cancer patients with febrile neutropenia: a randomized, double-blind trial. J Clin Oncol. 2000;18:3690–8.

    CAS  PubMed  Google Scholar 

  40. Fleischhack G, Hartmann C, Simon A, et al. Meropenem versus ceftazidime as empirical monotherapy in febrile neutropenia of paediatric patients with cancer. J Antimicrob Chemother. 2001;47:841–53.

    CAS  PubMed  Google Scholar 

  41. Fraschini F, Scaglione F, Falchi M, et al. Pharmacokinetics and tissue distribution of amoxicillin plus clavulanic acid after oral administration in man. J Chemother. 1990;2:171–7.

    CAS  PubMed  Google Scholar 

  42. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52:e56–93.

    PubMed  Google Scholar 

  43. Freifeld AG, Walsh T, Marshall D, et al. Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. J Clin Oncol. 1995;13:165–76.

    CAS  PubMed  Google Scholar 

  44. Fugate JE, Kalimullah EA, Hocker SE, et al. Cefepime neurotoxicity in the intensive care unit: a cause of severe, underappreciated encephalopathy. Crit Care. 2013;17:R264.

    PubMed Central  PubMed  Google Scholar 

  45. Fujisawa Y, Oyake T, Mine T, et al. Doripenem versus meropenem for empirical antimicrobial therapy in high risk febrile neutropenic patients with hematological malignancies: a randomized, controlled trial. ASH 2013 Annual Meeting Abstracts. Blood. 2013;122:4716.

    Google Scholar 

  46. Gafter-Gvili A, Fraser A, Paul M, et al. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev. 2012;(1):CD004386.

    Google Scholar 

  47. Garonzik SM, Li J, Thamlikitkul V, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother. 2011;55:3284–94.

    CAS  PubMed Central  PubMed  Google Scholar 

  48. Ghehi MT, Rezaee S, Hayatshahi A, et al. Vancomycin pharmacokinetic parameters in patients undergoing hematopoietic stem cell transplantation (HSCT). Int J Hematol Oncol Stem Cell Res. 2013;7:1–9.

    PubMed Central  PubMed  Google Scholar 

  49. Gibson J, Date L, Joshua DE, et al. A randomised trial of empirical antibiotic therapy in febrile neutropenic patients with hematological disorders: ceftazidime versus azlocillin plus amikacin. Aust N Z J Med. 1989;19:417–25.

    CAS  PubMed  Google Scholar 

  50. Goldberg E, Bishara J. Contemporary unconventional clinical use of co-trimoxazole. Clin Microbiol Infect. 2012;18:8–17.

    CAS  PubMed  Google Scholar 

  51. Hachem RY, Chemaly RF, Ahmar CA, et al. Colistin is effective in treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in cancer patients. Antimicrob Agents Chemother. 2007;51:1905–11.

    CAS  PubMed Central  PubMed  Google Scholar 

  52. Hachem RY, Hicks K, Huen A, et al. Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients. Clin Infect Dis. 2003;37:e8–11.

    CAS  PubMed  Google Scholar 

  53. Haeseker M, Stolk L, Nieman F, et al. The ciprofloxacin target AUC: MIC ratio is not reached in hospitalized patients with the recommended dosing regimens. Br J Clin Pharmacol. 2013;75:180–5.

    CAS  PubMed Central  PubMed  Google Scholar 

  54. Hatala R, Dinh TT, Cook DJ. Single daily dosing of aminoglycosides in immunocompromised adults: a systematic review. Clin Infect Dis. 1997;24:810–5.

    CAS  PubMed  Google Scholar 

  55. Imran H, Tleyjeh IM, Arndt CA, et al. Fluoroquinolone prophylaxis in patients with neutropenia: a meta-analysis of randomized placebo-controlled trials. Eur J Clin Microbiol Infect Dis. 2008;27:53–6.

    CAS  PubMed  Google Scholar 

  56. Jaksic B, Martinelli G, Perez-Oteyza J, et al. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin Infect Dis. 2006;42:597–607.

    CAS  PubMed  Google Scholar 

  57. Jaruratanasirikul S, Limapichat T, Jullangkoon M, et al. Pharmacodynamics of meropenem in critically ill patients with febrile neutropenia and bacteraemia. Int J Antimicrob Agents. 2011;38:231–6.

    CAS  PubMed  Google Scholar 

  58. Jaruratanasirikul S, Sriwiriyajan S, Punyo J. Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection. Antimicrob Agents Chemother. 2005;49:1337–9.

    CAS  PubMed Central  PubMed  Google Scholar 

  59. Jean SS, Lee WS, Bai KJ, et al. Relationship between the distribution of cefepime minimum inhibitory concentrations and detection of extended-spectrum β-lactamase production among clinically important Enterobacteriaceae isolates obtained from patients in intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2007. J Microbiol Immunol Infect. 2013. pii: S1684–1182(13)00118–7. doi: 10.1016/j.jmii.2013.07.002. [Epub ahead of print].

  60. Joshi L, Taylor SR, Large O, et al. A case of optic neuropathy after short-term linezolid use in a patient with acute lymphocytic leukemia. Clin Infect Dis. 2009;48:e73–4.

    PubMed  Google Scholar 

  61. Kahan FM, Kropp H, Sundelof JG, et al. Thienamycin: development of imipenem-cilastatin. J Antimicrob Chemother. 1983;12(Suppl D):1–35.

    CAS  PubMed  Google Scholar 

  62. Kalil AC. Is cefepime safe for clinical use? A Bayesian viewpoint. J Antimicrob Chemother. 2011;66:1207–9.

    CAS  PubMed  Google Scholar 

  63. Kern WV, Cometta A, de Bock R, et al. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the EORTC. N Engl J Med. 1999;341:312–8.

    CAS  PubMed  Google Scholar 

  64. Kern WV, Marchetti O, Drgona L, et al. Oral antibiotics for fever in low-risk neutropenic patients with cancer: a double-blind, randomized, multicenter trial comparing single daily moxifloxacin with twice daily ciprofloxacin plus amoxicillin/clavulanic acid combination therapy – EORTC Infectious Diseases Group Trial X. J Clin Oncol. 2013;31:1149–56.

    CAS  PubMed  Google Scholar 

  65. Kim PW, Wu YT, Cooper C, et al. Meta-analysis of a possible signal of increased mortality associated with cefepime use. Clin Infect Dis. 2010;51:381–9.

    PubMed  Google Scholar 

  66. Klinker H, Langmann P, Zilly M, et al. Drug monitoring during the treatment of AIDS-associated Pneumocystis carinii pneumonia with trimethoprim-sulfamethoxazole. J Clin Pharm Ther. 1998;23:149–54.

    CAS  PubMed  Google Scholar 

  67. Kullar R, Casapao AM, Davis SL, et al. A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis. J Antimicrob Chemother. 2013;68:2921–6.

    CAS  PubMed Central  PubMed  Google Scholar 

  68. Kuti JL, Nightingale CH, Knauft RF, et al. Pharmacokinetic properties and stability of continuous-infusion meropenem in adults with cystic fibrosis. Clin Ther. 2004;26:493–501.

    CAS  PubMed  Google Scholar 

  69. Kwon KT, Cheong HS, Rhee JY, et al. Panipenem versus cefepime as empirical monotherapy in adult cancer patients with febrile neutropenia: a prospective randomized trial. Jpn J Clin Oncol. 2008;38:49–55.

    PubMed  Google Scholar 

  70. Lai CC, Sheng WH, Wang JT, et al. Safety and efficacy of high-dose daptomycin as salvage therapy for severe gram-positive bacterial sepsis in hospitalized adult patients. BMC Infect Dis. 2013;13:66.

    CAS  PubMed Central  PubMed  Google Scholar 

  71. Landersdorfer CB, Kirkpatrick CM, Kinzig-Schippers M, et al. Population pharmacokinetics at two dose levels and pharmacodynamic profiling of flucloxacillin. Antimicrob Agents Chemother. 2007;51:3290–7.

    CAS  PubMed Central  PubMed  Google Scholar 

  72. Lee LS, Kinzig-Schippers M, Nafziger AN, et al. Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation. Diagn Microbiol Infect Dis. 2010;68:251–8.

    CAS  PubMed  Google Scholar 

  73. Leibovici L, Paul M, Cullen M, et al. Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions. Cancer. 2006;107:1743–51.

    CAS  PubMed  Google Scholar 

  74. Livermore DM, Warner M, Mushtaq S, et al. What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. Int J Antimicrob Agents. 2011;37:415–9.

    CAS  PubMed  Google Scholar 

  75. Luque S, Grau S, Valle M, et al. Differences in pharmacokinetics and pharmacodynamics of colistimethate sodium (CMS) and colistin between three different CMS dosage regimens in a critically ill patient infected by a multidrug-resistant acinetobacter baumannii. Int J Antimicrob Agents. 2013;42:178–81.

    CAS  PubMed  Google Scholar 

  76. MacVane SH, Kuti JL, Nicolau DP. Prolonging β-lactam infusion: a review of the rationale and evidence, and guidance for implementation. Int J Antimicrob Agents. 2014;43:105–13.

    CAS  PubMed  Google Scholar 

  77. Manji A, Lehrnbecher T, Dupuis LL, et al. A systematic review and meta-analysis of anti-pseudomonal penicillins and carbapenems in pediatric febrile neutropenia. Support Care Cancer. 2012;20:2295–304.

    PubMed  Google Scholar 

  78. Mareville J, Gay J, Cliquennois E, et al. Therapeutic drug monitoring of aminoglycosides in acute myeloid leukaemia patients. Scand J Infect Dis. 2012;44:398–401.

    CAS  PubMed  Google Scholar 

  79. Martínez JA, Cobos-Trigueros N, Soriano A, et al. Influence of empiric therapy with a beta-lactam alone or combined with an aminoglycoside on prognosis of bacteremia due to gram-negative microorganisms. Antimicrob Agents Chemother. 2010;54:3590–6.

    PubMed Central  PubMed  Google Scholar 

  80. Mavros MN, Polyzos KA, Rafailidis PI, et al. Once versus multiple daily dosing of aminoglycosides for patients with febrile neutropenia: a systematic review and meta-analysis. J Antimicrob Chemother. 2011;66:251–9.

    CAS  PubMed  Google Scholar 

  81. McKinnon PS, Paladino JA, Schentag JJ. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents. 2008;31:345–51.

    CAS  PubMed  Google Scholar 

  82. Micek ST, Welch EC, Khan J, et al. Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to gram-negative bacteria: a retrospective analysis. Antimicrob Agents Chemother. 2010;54:1742–8.

    CAS  PubMed Central  PubMed  Google Scholar 

  83. Munckhof WJ, Grayson ML, Turnidge JD. A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses. J Antimicrob Chemother. 1996;37:645–63.

    CAS  PubMed  Google Scholar 

  84. Nailor MD, Sobel JD. Antibiotics for gram-positive bacterial infections: vancomycin, teicoplanin, quinupristin/dalfopristin, oxazolidinones, daptomycin, dalbavancin, and telavancin. Med Clin North Am. 2011;95:723–42.

    CAS  PubMed  Google Scholar 

  85. Narita M, Tsuji BT, Yu VL. Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome. Pharmacotherapy. 2007;27:1189–97.

    CAS  PubMed  Google Scholar 

  86. Paul M, Dickstein Y, Schlesinger A, et al. Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia. Cochrane Database Syst Rev. 2013;(6):CD003038.

    Google Scholar 

  87. Paul M, Yahav D, Bivas A, et al. Anti-pseudomonal beta-lactams for the initial, empirical, treatment of febrile neutropenia: comparison of beta-lactams. Cochrane Database Syst Rev. 2010;(11):CD005197.

    Google Scholar 

  88. Pea F, Viale P, Damiani D, et al. Ceftazidime in acute myeloid leukemia patients with febrile neutropenia: helpfulness of continuous intravenous infusion in maximizing pharmacodynamic exposure. Antimicrob Agents Chemother. 2005;49:3550–3.

    CAS  PubMed Central  PubMed  Google Scholar 

  89. Pizzo PA, Hathorn JW, Hiemenz J, et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med. 1986;315:552–8.

    CAS  PubMed  Google Scholar 

  90. Plachouras D, Karvanen M, Friberg LE, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother. 2009;53:3430–6.

    CAS  PubMed Central  PubMed  Google Scholar 

  91. Poulikakos P, Falagas ME. Aminoglycoside therapy in infectious diseases. Expert Opin Pharmacother. 2013;14:1585–97.

    CAS  PubMed  Google Scholar 

  92. Quon BS, Goss CH, Ramsey BW. Inhaled antibiotics for lower airway infections. Ann Am Thorac Soc. 2014;11:425–34.

    CAS  PubMed  Google Scholar 

  93. Rangaraj G, Granwehr BP, Jiang Y, et al. Perils of quinolone exposure in cancer patients: breakthrough bacteremia with multidrug-resistant organisms. Cancer. 2010;116:967–73.

    PubMed  Google Scholar 

  94. Reed MD. Clinical pharmacokinetics of amoxicillin and clavulanate. Pediatr Infect Dis J. 1996;15:949–54.

    CAS  PubMed  Google Scholar 

  95. Rigge DC, Jones MF. Shelf lives of aseptically prepared medicines – stability of piperacillin/tazobactam in PVC and non-PVC bags. J Pharm Biomed Anal. 2005;39:339–43.

    CAS  PubMed  Google Scholar 

  96. Rodríguez-Baño J, Navarro MD, Retamar P, et al. β-lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis. 2012;54:167–74.

    PubMed  Google Scholar 

  97. Rodríguez-Baño J, Oteo J, Ortega A, et al. Epidemiological and clinical complexity of amoxicillin-clavulanate-resistant Escherichia coli. J Clin Microbiol. 2013;51:2414–7.

    PubMed Central  PubMed  Google Scholar 

  98. Rolston KV, Besece D, Lamp KC, et al. Daptomycin use in neutropenic patients with documented gram-positive infections. Support Care Cancer. 2014;22:7–14.

    PubMed  Google Scholar 

  99. Rolston KV, McConnell SA, Brown J, et al. Daptomycin use in patients with cancer and neutropenia: data from a retrospective registry. Clin Adv Hematol Oncol. 2010;8:249–56.

    PubMed  Google Scholar 

  100. Ryzner KL. Evaluation of aminoglycoside clearance using the modification of diet in renal disease equation versus the Cockcroft-Gault equation as a marker of glomerular filtration rate. Ann Pharmacother. 2010;44:1030–7.

    CAS  PubMed  Google Scholar 

  101. Safdar A, Rolston KV. Vancomycin tolerance, a potential mechanism for refractory gram-positive bacteremia observational study in patients with cancer. Cancer. 2006;106:1815–20.

    CAS  PubMed  Google Scholar 

  102. Schentag JJ, Plaut ME, Cerra FB. Comparative nephrotoxicity of gentamicin and tobramycin: pharmacokinetic and clinical studies in 201 patients. Antimicrob Agents Chemother. 1981;19:859–66.

    CAS  PubMed Central  PubMed  Google Scholar 

  103. Shea KM, Cheatham SC, Smith DW, et al. Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients. Ann Pharmacother. 2009;43:1747–54.

    CAS  PubMed  Google Scholar 

  104. Smith PF, Birmingham MC, Noskin GA, et al. Safety, efficacy and pharmacokinetics of linezolid for treatment of resistant gram-positive infections in cancer patients with neutropenia. Ann Oncol. 2003;14:795–801.

    CAS  PubMed  Google Scholar 

  105. Stein GE, Throckmorton JK, Scharmen AE, et al. Tissue penetration and antimicrobial activity of standard- and high-dose trimethoprim/sulfamethoxazole and linezolid in patients with diabetic foot infection. J Antimicrob Chemother. 2013;68:2852–8.

    CAS  PubMed  Google Scholar 

  106. Stephens C, López-Nevot M, Ruiz-Cabello F, et al. HLA alleles influence the clinical signature of amoxicillin-clavulanate hepatotoxicity. PLoS One. 2013;8:e68111.

    CAS  PubMed Central  PubMed  Google Scholar 

  107. Thabet F, Al Maghrabi M, Al Barraq A, et al. Cefepime-induced nonconvulsive status epilepticus: case report and review. Neurocrit Care. 2009;10:347–51.

    PubMed  Google Scholar 

  108. van de Wetering MD, de Witte MA, Kremer LC, et al. Efficacy of oral prophylactic antibiotics in neutropenic afebrile oncology patients: a systematic review of randomised controlled trials. Eur J Cancer. 2005;41:1372–82.

    PubMed  Google Scholar 

  109. Veeraraghavan B. Newer β-lactam and β-lactamase inhibitor combinations available in India: consensus and controversies. Indian J Med Microbiol. 2011;29:315–6.

    CAS  PubMed  Google Scholar 

  110. Velkov T, Roberts KD, Nation RL, et al. Pharmacology of polymyxins: new insights into an ‘old’ class of antibiotics. Future Microbiol. 2013;8:711–24.

    CAS  PubMed  Google Scholar 

  111. Vesole DH, Oken MM, Heckler C, et al. Oral antibiotic prophylaxis of early infection in multiple myeloma: a URCC/ECOG randomized phase III study. Leukemia. 2012;26:2517–20.

    CAS  PubMed  Google Scholar 

  112. Viaene E, Chanteux H, Servais H, et al. Comparative stability studies of antipseudomonal beta-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units). Antimicrob Agents Chemother. 2002;46:2327–32.

    CAS  PubMed Central  PubMed  Google Scholar 

  113. Viscoli C, Cometta A, Kern WV, et al. Piperacillin-tazobactam monotherapy in high-risk febrile and neutropenic cancer patients. Clin Microbiol Infect. 2006;12:212–6.

    CAS  PubMed  Google Scholar 

  114. Wolfensberger A, Sax H, Weber R, et al. Change of antibiotic susceptibility testing guidelines from CLSI to EUCAST: influence on cumulative hospital antibiograms. PLoS One. 2013;8:e79130.

    CAS  PubMed Central  PubMed  Google Scholar 

  115. Yahav D, Paul M, Fraser A, et al. Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet Infect Dis. 2007;7:338–48.

    CAS  PubMed  Google Scholar 

  116. Zhanel GG, Lawson CD, Adam H, et al. Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination. Drugs. 2013;73:159–77.

    CAS  PubMed  Google Scholar 

  117. Zhanel GG, Lawson CD, Zelenitsky S, et al. Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin. Expert Rev Anti Infect Ther. 2012;10:459–73.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Center for Infectious Diseases and Travel Medicine, IFB-Center for Chronic Immunodeficiency, University Hospital, Hugstetter Strasse 55, D-79106, Freiburg, Germany

    Winfried V. Kern

Authors
  1. Winfried V. Kern
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Winfried V. Kern .

Editor information

Editors and Affiliations

  1. Department of Hematology, Oncology and Palliative Care, Klinikum Ernst von Bergmann, Potsdam, Germany

    Georg Maschmeyer

  2. Department of Infectious Diseases, Infection Control and Employee Health, M.D. Anderson Cancer Center University of Texas, Houston, Texas, USA

    Kenneth V.I. Rolston

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Kern, W.V. (2015). Antibacterial Agents. In: Maschmeyer, G., Rolston, K. (eds) Infections in Hematology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-44000-1_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-44000-1_14

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-43999-9

  • Online ISBN: 978-3-662-44000-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation